A Letter from Prodigy’s CEO to the DEA

Moving cannabis to Schedule III would mark a significant advancement in U.S. cannabis reform—a change supported by 88% of Americans according to Pew Research. The reclassification invites pharmaceutical companies into the mix, driving research and development, and necessitating FDA approval for cannabis-derived products which will require a prescription to comply with Schedule III. The advent of federal regulation is set to substantially enhance both product quality and consumer safety, potentially redefining the medical marijuana industry, which has until now been monitored only by local health departments that lack the subject matter expertise and broad reach of the FDA.

The FDA’s regulatory acumen will play a crucial role in fulfilling the need for standardization and stringent consumer safety standards that has long been overlooked. From its inception, Prodigy has only designed and manufactured cannabis and hemp extraction equipment that not only complies with but exceeds pharmaceutical and cGMP standards, thereby seamlessly aligning the FDA’s stringent regulations with our dedication to consumer safety.

Public comments to the DEA on rescheduling cannabis from Schedule I to Schedule III ended a day ago with a remarkable 42,925 submissions from interested parties. PRODIGY chimed in with strong support of the measure due to the massive opportunities it will create for forward-looking extraction labs that step up to pharmaceutical FDA cGMP standards and obtain DEA registration. These pioneers will be able to flourish across state lines and over international borders with new product lines and revenue streams that have incredible, previously unattainable, ROI in the cannabis industry.

If your lab is ready to go pharma GMP, we’ll get you there in record speed!

Marc Beginin – Founder/CEO, Prodigy Processing Solutions